Drugmaker Incyte Corp reported fourth-quarter revenue above Wall Street estimates on Monday, boosted by strong demand for its key blood-cancer drug Jakafi and skin-disorder treatment Opzelura.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback